{
    "id": 7041,
    "fullName": "HSP90AA1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "HSP90AA1 over exp indicates an over expression of the Hsp90aa1 (Hsp90-alpha) protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3320,
        "geneSymbol": "HSP90AA1",
        "terms": [
            "HSP90AA1",
            "EL52",
            "HEL-S-65p",
            "Hsp103",
            "HSP86",
            "Hsp89",
            "HSP89A",
            "Hsp90",
            "HSP90A",
            "HSP90N",
            "HSPC1",
            "HSPCA",
            "HSPCAL1",
            "HSPCAL4",
            "HSPN",
            "LAP-2",
            "LAP2"
        ]
    },
    "variant": "over exp",
    "createDate": "06/04/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4433,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Luminespib (AUY922) induced apoptosis in colorectal cancer cell lines with high Hsp90 expression in culture (PMID: 25982393).",
            "molecularProfile": {
                "id": 6899,
                "profileName": "HSP90AA1 over exp"
            },
            "therapy": {
                "id": 647,
                "therapyName": "Luminespib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4538,
                    "pubMedId": 25982393,
                    "title": "Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25982393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4649,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CPUY201112 inhibited proliferation and induced apoptosis in human breast cancer cell lines with high Hsp90 expression in culture, and inhibited tumor growth in human breast cancer xenograft models (PMID: 26743233).",
            "molecularProfile": {
                "id": 6899,
                "profileName": "HSP90AA1 over exp"
            },
            "therapy": {
                "id": 3589,
                "therapyName": "CPUY201112",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4657,
                    "pubMedId": 26743233,
                    "title": "CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6346,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF4942847 inhibited proliferation and induced apoptosis in osteosarcoma cell lines over expressing Hsp90 in culture, and reduced tumor growth and metastasis in cell line xenograft models (PMID: 26712686).",
            "molecularProfile": {
                "id": 6899,
                "profileName": "HSP90AA1 over exp"
            },
            "therapy": {
                "id": 4120,
                "therapyName": "PF4942847",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5536,
                    "pubMedId": 26712686,
                    "title": "Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26712686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6347,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF4942847 and Zometa (zoledronic acid) worked synergistically to inhibit proliferation in osteosarcoma cell lines over expressing Hsp90 in culture, and to reduce tumor growth, metastasis and bone lesions in cell line xenograft models (PMID: 26712686).",
            "molecularProfile": {
                "id": 6899,
                "profileName": "HSP90AA1 over exp"
            },
            "therapy": {
                "id": 4121,
                "therapyName": "PF4942847 + Zoledronic acid",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5536,
                    "pubMedId": 26712686,
                    "title": "Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26712686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6899,
            "profileName": "HSP90AA1 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 5038,
                    "name": "HSP90 Inhibitor",
                    "profileName": "HSP90AA1 over exp"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}